rs190132116

Variant summary

Our verdict is Benign. The variant received -19 ACMG points: 0P and 19B. BP4_ModerateBP6_Very_StrongBP7BS1BS2

The NM_002047.4(GARS1):​c.2190G>A​(p.Glu730Glu) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000772 in 1,595,330 control chromosomes in the GnomAD database, including 8 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.0041 ( 5 hom., cov: 31)
Exomes 𝑓: 0.00042 ( 3 hom. )

Consequence

GARS1
NM_002047.4 synonymous

Scores

2

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:6

Conservation

PhyloP100: 3.48

Publications

1 publications found
Variant links:
Genes affected
GARS1 (HGNC:4162): (glycyl-tRNA synthetase 1) This gene encodes glycyl-tRNA synthetase, one of the aminoacyl-tRNA synthetases that charge tRNAs with their cognate amino acids. The encoded enzyme is an (alpha)2 dimer which belongs to the class II family of tRNA synthetases. It has been shown to be a target of autoantibodies in the human autoimmune diseases, polymyositis or dermatomyositis. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2015]
GARS1 Gene-Disease associations (from GenCC):
  • Charcot-Marie-Tooth disease type 2D
    Inheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: ClinGen, Labcorp Genetics (formerly Invitae), Orphanet
  • neuronopathy, distal hereditary motor, type 5A
    Inheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), Illumina, Laboratory for Molecular Medicine
  • spinal muscular atrophy, infantile, James type
    Inheritance: AD Classification: MODERATE Submitted by: Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -19 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.41).
BP6
Variant 7-30633830-G-A is Benign according to our data. Variant chr7-30633830-G-A is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 377913.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=3.47 with no splicing effect.
BS1
Variant frequency is greater than expected in population afr. GnomAd4 allele frequency = 0.0041 (619/151086) while in subpopulation AFR AF = 0.0143 (591/41228). AF 95% confidence interval is 0.0134. There are 5 homozygotes in GnomAd4. There are 300 alleles in the male GnomAd4 subpopulation. Median coverage is 31. This position passed quality control check.
BS2
High AC in GnomAd4 at 619 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
GARS1NM_002047.4 linkc.2190G>A p.Glu730Glu synonymous_variant Exon 17 of 17 ENST00000389266.8 NP_002038.2 P41250-1
GARS1NM_001316772.1 linkc.2028G>A p.Glu676Glu synonymous_variant Exon 17 of 17 NP_001303701.1 P41250-2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
GARS1ENST00000389266.8 linkc.2190G>A p.Glu730Glu synonymous_variant Exon 17 of 17 1 NM_002047.4 ENSP00000373918.3 P41250-1
GARS1ENST00000675651.1 linkc.2208G>A p.Glu736Glu synonymous_variant Exon 17 of 17 ENSP00000502513.1 A0A6Q8PGZ8
GARS1ENST00000675810.1 linkc.2088G>A p.Glu696Glu synonymous_variant Exon 16 of 16 ENSP00000502743.1 A0A6Q8PHH9
GARS1ENST00000675693.1 linkc.2022G>A p.Glu674Glu synonymous_variant Exon 18 of 18 ENSP00000502174.1 A0A6Q8PGA8
GARS1ENST00000675051.1 linkc.1989G>A p.Glu663Glu synonymous_variant Exon 17 of 17 ENSP00000502296.1 A0A6Q8PGI6
GARS1ENST00000674815.1 linkc.1821G>A p.Glu607Glu synonymous_variant Exon 17 of 17 ENSP00000502799.1 A0A6Q8PGW4
GARS1ENST00000674851.1 linkc.1821G>A p.Glu607Glu synonymous_variant Exon 18 of 18 ENSP00000502451.1 A0A6Q8PGW4
GARS1ENST00000444666.6 linkn.*611G>A non_coding_transcript_exon_variant Exon 18 of 18 3 ENSP00000415447.2 H7C443
GARS1ENST00000674616.1 linkn.*1904G>A non_coding_transcript_exon_variant Exon 18 of 18 ENSP00000502408.1 A0A6Q8PGT3
GARS1ENST00000674643.1 linkn.*1995G>A non_coding_transcript_exon_variant Exon 17 of 17 ENSP00000501636.1 A0A6Q8PF45
GARS1ENST00000674737.1 linkn.*1528G>A non_coding_transcript_exon_variant Exon 18 of 18 ENSP00000502464.1 A0A6Q8PGZ9
GARS1ENST00000674807.1 linkn.*463G>A non_coding_transcript_exon_variant Exon 16 of 16 ENSP00000502814.1 A0A6Q8PFZ6
GARS1ENST00000675529.1 linkn.*2060G>A non_coding_transcript_exon_variant Exon 18 of 18 ENSP00000501655.1 A0A6Q8PFN0
GARS1ENST00000675859.1 linkn.*369G>A non_coding_transcript_exon_variant Exon 15 of 15 ENSP00000502033.1 A0A6Q8PFZ6
GARS1ENST00000676088.1 linkn.*2132G>A non_coding_transcript_exon_variant Exon 19 of 19 ENSP00000501884.1 A0A6Q8PFN0
GARS1ENST00000676140.1 linkn.*1135G>A non_coding_transcript_exon_variant Exon 17 of 17 ENSP00000502571.1 A0A6Q8PH49
GARS1ENST00000676164.1 linkn.*1641G>A non_coding_transcript_exon_variant Exon 17 of 17 ENSP00000501986.1 A0A6Q8PFV5
GARS1ENST00000676210.1 linkn.*1479G>A non_coding_transcript_exon_variant Exon 18 of 18 ENSP00000502373.1 A0A6Q8PGN7
GARS1ENST00000676259.1 linkn.*1622G>A non_coding_transcript_exon_variant Exon 17 of 17 ENSP00000501980.1 A0A6Q8PFU7
GARS1ENST00000676403.1 linkn.*275G>A non_coding_transcript_exon_variant Exon 16 of 16 ENSP00000502681.1 A0A6Q8PHI7
GARS1ENST00000444666.6 linkn.*611G>A 3_prime_UTR_variant Exon 18 of 18 3 ENSP00000415447.2 H7C443
GARS1ENST00000674616.1 linkn.*1904G>A 3_prime_UTR_variant Exon 18 of 18 ENSP00000502408.1 A0A6Q8PGT3
GARS1ENST00000674643.1 linkn.*1995G>A 3_prime_UTR_variant Exon 17 of 17 ENSP00000501636.1 A0A6Q8PF45
GARS1ENST00000674737.1 linkn.*1528G>A 3_prime_UTR_variant Exon 18 of 18 ENSP00000502464.1 A0A6Q8PGZ9
GARS1ENST00000674807.1 linkn.*463G>A 3_prime_UTR_variant Exon 16 of 16 ENSP00000502814.1 A0A6Q8PFZ6
GARS1ENST00000675529.1 linkn.*2060G>A 3_prime_UTR_variant Exon 18 of 18 ENSP00000501655.1 A0A6Q8PFN0
GARS1ENST00000675859.1 linkn.*369G>A 3_prime_UTR_variant Exon 15 of 15 ENSP00000502033.1 A0A6Q8PFZ6
GARS1ENST00000676088.1 linkn.*2132G>A 3_prime_UTR_variant Exon 19 of 19 ENSP00000501884.1 A0A6Q8PFN0
GARS1ENST00000676140.1 linkn.*1135G>A 3_prime_UTR_variant Exon 17 of 17 ENSP00000502571.1 A0A6Q8PH49
GARS1ENST00000676164.1 linkn.*1641G>A 3_prime_UTR_variant Exon 17 of 17 ENSP00000501986.1 A0A6Q8PFV5
GARS1ENST00000676210.1 linkn.*1479G>A 3_prime_UTR_variant Exon 18 of 18 ENSP00000502373.1 A0A6Q8PGN7
GARS1ENST00000676259.1 linkn.*1622G>A 3_prime_UTR_variant Exon 17 of 17 ENSP00000501980.1 A0A6Q8PFU7
GARS1ENST00000676403.1 linkn.*275G>A 3_prime_UTR_variant Exon 16 of 16 ENSP00000502681.1 A0A6Q8PHI7

Frequencies

GnomAD3 genomes
AF:
0.00410
AC:
619
AN:
150958
Hom.:
4
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.0144
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00112
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000118
Gnomad OTH
AF:
0.00144
GnomAD2 exomes
AF:
0.00102
AC:
255
AN:
249482
AF XY:
0.000879
show subpopulations
Gnomad AFR exome
AF:
0.0137
Gnomad AMR exome
AF:
0.000898
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.0000464
Gnomad NFE exome
AF:
0.0000353
Gnomad OTH exome
AF:
0.000825
GnomAD4 exome
AF:
0.000424
AC:
613
AN:
1444244
Hom.:
3
Cov.:
41
AF XY:
0.000384
AC XY:
276
AN XY:
718396
show subpopulations
African (AFR)
AF:
0.0146
AC:
478
AN:
32770
American (AMR)
AF:
0.000817
AC:
36
AN:
44090
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
25402
East Asian (EAS)
AF:
0.00
AC:
0
AN:
38510
South Asian (SAS)
AF:
0.0000465
AC:
4
AN:
86094
European-Finnish (FIN)
AF:
0.0000392
AC:
2
AN:
51048
Middle Eastern (MID)
AF:
0.000529
AC:
3
AN:
5672
European-Non Finnish (NFE)
AF:
0.0000381
AC:
42
AN:
1101436
Other (OTH)
AF:
0.000811
AC:
48
AN:
59222
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.455
Heterozygous variant carriers
0
33
65
98
130
163
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00410
AC:
619
AN:
151086
Hom.:
5
Cov.:
31
AF XY:
0.00406
AC XY:
300
AN XY:
73802
show subpopulations
African (AFR)
AF:
0.0143
AC:
591
AN:
41228
American (AMR)
AF:
0.00112
AC:
17
AN:
15190
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5070
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4672
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10334
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.000118
AC:
8
AN:
67806
Other (OTH)
AF:
0.00142
AC:
3
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.508
Heterozygous variant carriers
0
30
59
89
118
148
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00177
Hom.:
0
Bravo
AF:
0.00443
Asia WGS
AF:
0.000289
AC:
1
AN:
3478
EpiCase
AF:
0.0000545
EpiControl
AF:
0.0000593

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:2
Jul 11, 2019
Ambry Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Apr 26, 2016
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

not provided Benign:2
Dec 12, 2017
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Mar 31, 2022
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Charcot-Marie-Tooth disease type 2 Benign:1
Jan 06, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

GARS1-related disorder Benign:1
Jul 08, 2019
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.41
CADD
Benign
7.2
DANN
Benign
0.52
PhyloP100
3.5
Mutation Taster
=100/0
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs190132116; hg19: chr7-30673446; API